IP Library Granted Patent US 8,012,477
Granted Patent B2
US 8,012,477 · App. 12/223,050 · Granted Sep 6, 2011

Methods of treating multiple myeloma using IL-17 binding molecules

Assignees: Novartis AG; Novartis Pharma GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,012,477
App. No.
12/223,050
Granted
Sep 6, 2011
Kind
B2
Abstract

An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of a solid or hematological malignant diseases.

Claims (10)

1. A method of treating multiple myeloma, comprising administering to a patient in need thereof a therapeutically effective amount of an IL-17 antibody or antigen binding fragment thereof comprising:

a. a heavy (V H ) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:8;

b. a light (V L ) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:10;

c. a heavy (V H ) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:8 and a light (V L ) chain variable domain comprising the amino acid sequence set forth as SEQ ID NO:10; or

d. the three Complementarity-Determining Regions (CDRs) of the amino acid sequence set forth as SEQ ID NO:8 and the three CDRs of the amino acid sequence set forth as SEQ ID NO:10.

2. The method as set forth in claim 1 , wherein the three CDRs of the amino acid sequence set forth as SEQ ID NO:8 are set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

3. The method as set forth in claim 1 , wherein the three CDRs of the amino acid sequence set forth as SEQ ID NO:8 are set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13.

4. The method as set forth in claim 1 , wherein the three CDRs of the amino acid sequence set forth as SEQ ID NO:10 are set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.

5. The method as set forth in claim 1 , wherein the IL-17 antibody or antigen binding fragment thereof is a human antibody.

6. The method as set forth in claim 1 , wherein the IL-17 antibody or antigen binding fragment thereof is a human antibody comprising the three CDRs of the amino acid sequence set forth as SEQ ID NO:8 and the three CDRs of the amino acid sequence set forth as SEQ ID NO:10.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2011
From: COOREMAN, MICHAEL; DI PADOVA, FRANCO E
To: NOVARTIS AG; NOVARTIS PHARMA GMBH
Reel/Frame 026283/0961 →
Continuity (2)
Provisional Application 60763673 · Jan 31, 2006
Related Publication 20100266608A1 · Oct 21, 2010